
Helus Pharma Touts Positive Data for Depression Drug
Summary
Helus Pharma announced favorable topline data from a late-stage clinical trial evaluating its experimental depression treatment. The study showed that the novel drug candidate effectively and quickly decreased symptoms in adults diagnosed with major depressive disorder.
Helus Pharma Inc. (NASDAQ:HELP) reported topline results from its pivotal Phase 3 APPROACH trial, showing its novel serotonergic agonist HLP003 rapidly and durably reduced symptoms in adults with major depressive disorder. Chief Executive Officer Michael Halstead said patients with persistent depression symptoms face a major unmet need for fast-acting, well-tolerated adjunctive therapies. Halstead emphasized that these trial results demonstrate a…
Source: Read the full story at Top Stories Feed